Cervical dystonia is a painful and disabling chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck.1
DAXXIFY® is currently under regulatory review for the treatment of cervical dystonia. The acceptance was supported by data from the ASPEN Phase 3 clinical program evaluating the efficacy and safety of DAXXIFY® for the treatment of cervical dystonia. The results support the potential use of DAXXIFY® as a new treatment option for cervical dystonia, where duration of painful symptom relief is a significant unmet need. 3,6
Cervical Dystonia in Numbers
40-60 years of age
Women to Men
Women are twice as likely to be affected by cervical dystonia
An estimated 60,000 Americans suffer from cervical dystonia
Learn More About Cervical Dystonia with Dr. Joseph Jankovic video
* Not an actual patient
71% of patients desire longer lasting benefits between treatments2
Revance Announces Top-Line Results for ASPEN-1
DAXXIFY® is currently under regulatory review for the treatment of cervical dystonia. The acceptance was supported by data from the ASPEN Phase 3 program, which includes the ASPEN-1 and ASPEN-OLS studies.
ASPEN-1 is a Phase 3, randomized, double-blind, placebo-controlled, parallel group clinical trial evaluating the efficacy and safety of DAXXIFY® for Injection for the treatment of cervical dystonia in adults.
ASPEN-1 study results suggest that DAXXIFY® for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually.2,6
The study met the primary endpoint demonstrating a statistically significant improvement in the averaged change in total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score at weeks 4 and 6 compared to placebo. TWSTRS was used to assess each patient’s severity, disability and pain caused by cervical dystonia.
ASPEN-OLS is a Phase 3, open-label, long-term safety trial during which subjects were eligible to receive up to 4 treatments over a 52-week period. ASPEN-OLS met the primary and secondary endpoints finding that DAXXIFY® was well tolerated and demonstrated safety and efficacy and further confirming the safety findings reported from the Phase 3 ASPEN-1 study.
Met the primary endpoint demonstrating a statistically significant improvement in the averaged change in TWSTRS-total score at weeks 4 and 6 compared to placebo.
Median Duration of Effect up to 24 weeks with 125U dose of DaxibotulinumtoxinA for Injection.
No unexpected adverse events were observed. The three most common treatment-related adverse events (for 125 Units and 250 Units) were injection site pain (7.9%, 4.7%), headache (4.7%, 4.7%), and injection site erythema (4.7%, 2.3%).
Other Common Adverse Events (for 125 Units and 250 Units) were Dysphagia (1.6%, 3.9%) and muscular weakness (4.7%, 2.3%).
DaxibotulinumtoxinA for Injection was approved by the FDA in [MM/YY] for the [insert based on label] and is currently being evaluated in additional therapeutic and aesthetic indications.
1 – Dystonia Medical Research Foundation. Retrieved from: https://dystonia-foundation.org/what-is-dystonia/types-dystonia/cervical-dystonia/. Accessed 8/11/20
2 – Comella, C., Ferreira, J.J., Pain, E. et al. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol (2020). https://doi.org/10.1007/s00415-020-10217-7
3 – Revance® Market Research 2019: Understanding the Value of DaxibotulinumtoxinA for Injections’ Therapeutic Franchise
4 – NORD (National Organization for Rare Disorders). Cervical Dystonia (July 19, 2019) Retrieved from: https://rarediseases.org/rare-diseases/cervical-dystonia/. Accessed 9/29/20
5 – Marsh W, et al. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurology 2014
6 – Data on File. ASPEN-1 CSR. Newark, CA: Revance Therapeutics, Inc., 2021.
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines.
IMPORTANT SAFETY INFORMATION
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.
Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.
Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.